Prostate Cancer Centre

Calgary, Alberta T2V1P9

5 studies enrolling now · 15 studies all time

What they study most

Biochemically Recurrent Prostate Cancer, Cancer, Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Intermediate Risk Non-Muscle Invasive Bladder Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Non-muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Performance Assessment of Novel Test, Prostate Cancer

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy — Running, not enrolling
• Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer — Running, not enrolling
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies — Running, not enrolling
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling
• EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC — Stopped early
• A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) — Stopped early
• Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer — Completed